4.6 Article

APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis

Journal

MOLECULAR NEURODEGENERATION
Volume 16, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13024-021-00483-y

Keywords

APOE; Apolipoprotein E; Aerobic glycolysis; Energy expenditure; Metabolism; Alzheimer's disease

Categories

Funding

  1. National Institute on Aging [BCF-F30AG06342201A, HCW-1T32AG057461-01, JMM -1RF1NS118558-01, LAJ -1R01AG060056, R01AG062550]
  2. National Institute of General Medical Sciences [HCW-5T32GM118292-03, LAJ-COBRE P20 GM103527, RCS COBRE P20 GM121327]
  3. National Institute of Neurological Disorders and Stroke [MSG -R01NS070899, R01NS070899-09S2, R35NS116824]
  4. American Cancer Society Institutional Research Grant [16-182-28]
  5. St Baldrick's Foundation
  6. National Center for Advancing Translational Sciences, National Institutes of Health [UL1TR001998]
  7. Redox Metabolism Shared Resource Facility of the University of Kentucky Markey Cancer Center [P30CA177558]

Ask authors/readers for more resources

Cerebral glucose hypometabolism is consistently observed in individuals with Alzheimer's disease (AD) and young cognitively normal carriers of the Epsilon 4 allele of Apolipoprotein E (APOE). The mechanism underlying these changes involves a shift towards increased aerobic glycolysis, particularly in astrocytes, leading to decreased pyruvate entry into the TCA cycle and increased lactate synthesis. This metabolic rewiring is observable in both mice and human subjects expressing APOE4, suggesting a potential early metabolic endophenotype prior to clinically manifest AD in young females.
Background Cerebral glucose hypometabolism is consistently observed in individuals with Alzheimer's disease (AD), as well as in young cognitively normal carriers of the Epsilon 4 allele of Apolipoprotein E (APOE), the strongest genetic predictor of late-onset AD. While this clinical feature has been described for over two decades, the mechanism underlying these changes in cerebral glucose metabolism remains a critical knowledge gap in the field. Methods Here, we undertook a multi-omic approach by combining single-cell RNA sequencing (scRNAseq) and stable isotope resolved metabolomics (SIRM) to define a metabolic rewiring across astrocytes, brain tissue, mice, and human subjects expressing APOE4. Results Single-cell analysis of brain tissue from mice expressing human APOE revealed E4-associated decreases in genes related to oxidative phosphorylation, particularly in astrocytes. This shift was confirmed on a metabolic level with isotopic tracing of C-13-glucose in E4 mice and astrocytes, which showed decreased pyruvate entry into the TCA cycle and increased lactate synthesis. Metabolic phenotyping of E4 astrocytes showed elevated glycolytic activity, decreased oxygen consumption, blunted oxidative flexibility, and a lower rate of glucose oxidation in the presence of lactate. Together, these cellular findings suggest an E4-associated increase in aerobic glycolysis (i.e. the Warburg effect). To test whether this phenomenon translated to APOE4 humans, we analyzed the plasma metabolome of young and middle-aged human participants with and without the Epsilon 4 allele, and used indirect calorimetry to measure whole body oxygen consumption and energy expenditure. In line with data from E4-expressing female mice, a subgroup analysis revealed that young female E4 carriers showed a striking decrease in energy expenditure compared to non-carriers. This decrease in energy expenditure was primarily driven by a lower rate of oxygen consumption, and was exaggerated following a dietary glucose challenge. Further, the stunted oxygen consumption was accompanied by markedly increased lactate in the plasma of E4 carriers, and a pathway analysis of the plasma metabolome suggested an increase in aerobic glycolysis. Conclusions Together, these results suggest astrocyte, brain and system-level metabolic reprogramming in the presence of APOE4, a 'Warburg like' endophenotype that is observable in young females decades prior to clinically manifest AD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available